A co-founder of VisEn, Dr. Weissleder is a Professor at Harvard Medical School, Director of both the Center for Molecular Imaging Research and the Center for Systems Biology at Massachusetts General Hospital (MGH) and Attending Interventional Radiologist at MGH. He has published over 500 peer-reviewed articles. He is a founding member of the Society for Molecular Imaging Research and has served as its President in 2002. He is the recipient of numerous scientific awards including the Allyn Taylor Prize in International Medicine, an SMI Lifetime Achievement Award and a Millenium Innovator in Medicine award. Scientifically, he is known for his significant contributions to molecular imaging research. Most of his profoundly impacting work has been aimed at cancer, atherosclerosis and inflammatory diseases and has led to new approaches on how these diseases are approached and managed. His research has been highly translational and some of his developments have led to advanced clinical trials with anticipated major impacts when these methods become routinely available. More information on Dr. Weissleder and his work at the MGH can be found on: cmir.mgh.harvard.edu and csb.mgh.harvard.edu

Dr. Rudin joined VisEn's Scientific Advisory Board in August 2006. He is Professor of Molecular Imaging and Functional Pharmacology at both the University of Zurich and the ETH Zurich (Swiss Federal Institute of Technology), Switzerland, and was formerly head of Imaging Technologies at Novartis. Prior to his academic career, Dr. Rudin was head of an MR imaging laboratory and later head of the Biophysics Group at Sandoz AG. In 1996, he became head of the In-vivo Models Unit and in 2000 head of the Analytical and Imaging Science Unit within Discovery Technologies at the Novartis Institutes for Biomedical Research.

Dr. Ginsburg joined VisEn's Scientific Advisory Board in December 2006. He is Professor of Medicine and Pathology and Director of the Center for Genomic Medicine at Duke University's Institute for Genome Sciences & Policy. Dr. Ginsburg's work centers on the identification and application of predictive biomarkers in developing and applying novel therapies and for improved research and clinical medicine. Prior to his academic career, he was Director of Cardiovascular Disease and Vice President of Molecular and Personalized Medicine at Millennium Pharmaceuticals. In these roles, he was responsible for Millennium's personalized medicine initiatives to develop biomarkers for disease and pharmacogenomic strategies for therapeutics and their implementation in the drug development process. His responsibilities also included translational research efforts and strategic academic alliances required to integrate genomics into the practice of medicine.